On the last day of February, millions of people came together globally to honor Rare Disease Day. It’s a day dedicated to raising awareness of rare diseases, the impact they have on people’s lives and the importance of developing treatments to improve quality of life for patients and families around the world. The National Institutes…
For many in the field of cell and gene therapy, 2020 had a singular theme: COVID-19. Dozens of clinical and preclinical trials were launched in labs around the world to test the efficacy of cell therapies to target complications from COVID-19 infection. But while the pandemic drew most of the media attention, it wasn’t the…
Breakthroughs in next-generation cell therapies have continued to progress rapidly over the past several years. Currently, more than 1,000 cell and gene therapies are in clinical studies. These therapies have the potential to transform the lives of people living with cancer and other diseases. The ONE Forum® 2020 highlighted new cell and gene therapy research…
Sourcing your starting material from high-quality, healthy donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your allogeneic therapy’s development. That makes your choice of a cell sourcing vendor critically important. Our team has sourced and collected cells for time critical cell therapies from more than 100,000 volunteer…
The progress toward more effective cell therapies for cancer in recent years has been astounding. Leading the way are chimeric antigen receptor T-cell (CAR-T) therapies. The exploration of CAR-T has opened new doors for treating numerous forms of cancer and other diseases. Recently, the FDA approved TecartusTM. This CAR-T therapy is intended to treat relapsed…
For Be The Match BioTherapies® CEO Amy Ronneberg, the path to becoming named one of the Top 25 BioTech CEOs of 2020 by TechCEOs was filled with twists and turns. Growing up in a small town in Wisconsin, she never imagined a degree in Accounting would someday lead her to one of today’s fastest growing…
As your cell or gene therapy operations scale from early-phase clinical trials to larger populations in late-stage trials and commercialization, your supply chain complexity — and risk — increases. Anticipating common setbacks and actively planning for their solution requires a specialized and collaborative approach with your supply chain partner. Keep these key considerations top of…
There is no question the COVID-19 pandemic has disrupted cell therapy logistics like never before. Supply chain challenges are no longer the exception, but the norm. So how can companies overcome autologous cell therapy logistics challenges to deliver time-sensitive source material and manufactured therapies on time? It’s not easy in our current environment, but it…
As the world responds to the COVID-19 pandemic, a growing number of biotech companies are pursuing clinical trials to determine the efficacy of using cell therapies to halt the virus’s deadly march. One such example is the use of mesenchymal stem cells (MSCs), multipotent stem cells found in a variety of tissues such as bone…